Characterization of a Novel BTD Hypomorphic Variant in a Patient with Complex Neurodevelopmental Delay: Resolving Actionable Metabolic Vulnerabilities Beyond Borderline Plasma Biochemistry
International Journal of Molecular Sciences · 30.07.2026 · 27 (15) · 6847
DOI: 10.3390/ijms27156847 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.07.2026. Verfasst von Claudia Toledo-Pacheco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Genética, Hospital Universitario de Toledo (HUT), 45007 Toledo, Spain. Hauptthemen laut MEDLINE: Biotinidase, Neurodevelopmental Disorders, Biotinidase Deficiency. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servicio de Salud de Castilla-La Mancha, Asociación para la difusión de Avances Oncológicos.
Abstract (Originalsprache)
Plasma biochemistry often presents significant limitations in diagnosing borderline metabolic disorders, particularly within complex neurodevelopmental phenotypes. Here, we present the clinical genomic evaluation of a six-year patient presenting with early-onset hypotonia and severe gastrointestinal complications whose newborn screening panel did not evaluate biotinidase (BTD) activity. While initial baseline plasma biochemistry yielded borderline residual BTD function (46% of the population mean), targeted sequencing identified a novel, compound heterozygous hypomorphic variant (p.Thr459Met) in trans with the common p.Asp424His allele. In vitro functional validation confirmed that p.Thr459Met induces severe protein misfolding and intracellular retention, impairing enzyme secretion. Biotin supplementation triggered a documented and favorable therapeutic improvement, establishing this borderline enzymatic background as an actionable metabolic vulnerability unmasked by chronic gastrointestinal stressors. This study underscores the critical value of functional genomic characterization over static enzymatic biomarkers to identify highly treatable metabolic components within heterogeneous clinical landscapes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Genética, Hospital Universitario de Toledo (HUT), 45007 Toledo, Spain.
- Instituto de Biomedicina, Universidad de Castilla-La Mancha (UCLM), 02008 Albacete, Spain.
- Facultad de Medicina CR, Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain.
- Facultad de Medicina AB, Universidad de Castilla-La Mancha (UCLM), 02008 Albacete, Spain.
ORCID-Profile: Claudia Toledo-Pacheco, Carles de Diego-Boguñá
Förderung
- Servicio de Salud de Castilla-La Mancha
- Asociación para la difusión de Avances Oncológicos
Zitieren
APA
Toledo-Pacheco, C., Montero-Hernández, M., López-Garrido, M. P., de Diego-Boguñá, C., & Sánchez-Sánchez, F. (2026). Characterization of a Novel BTD Hypomorphic Variant in a Patient with Complex Neurodevelopmental Delay: Resolving Actionable Metabolic Vulnerabilities Beyond Borderline Plasma Biochemistry. International Journal of Molecular Sciences, 27(15), 6847. https://doi.org/10.3390/ijms27156847
Vancouver
Toledo-Pacheco C, Montero-Hernández M, López-Garrido MP, de Diego-Boguñá C, Sánchez-Sánchez F. Characterization of a Novel BTD Hypomorphic Variant in a Patient with Complex Neurodevelopmental Delay: Resolving Actionable Metabolic Vulnerabilities Beyond Borderline Plasma Biochemistry. International Journal of Molecular Sciences. 2026;27(15):6847. doi:10.3390/ijms27156847
BibTeX
@article{ToledoPacheco2026,
author = {Toledo-Pacheco, Claudia and Montero-Hernández, Minerva and López-Garrido, María Pilar and de Diego-Boguñá, Carles and Sánchez-Sánchez, Francisco},
title = {Characterization of a Novel BTD Hypomorphic Variant in a Patient with Complex Neurodevelopmental Delay: Resolving Actionable Metabolic Vulnerabilities Beyond Borderline Plasma Biochemistry},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6847},
doi = {10.3390/ijms27156847}
}
EUVIMED